Hamlet Pharma’s achievements are emphasized after EU evaluation. The company has fully achieved its milestones and secured the second payment
We are proud to share the positive comments from the EIC Accelerator Horizon 2020 fund. The experienced EU evaluators state that:
“All required milestones and deliverables to date are without any significant deviations. This is particularly impressive in light of the global Corona virus pandemic.
To date, the beneficiary has succeeded in manufacturing the Investigational Medicinal Product (IMP) Alpa1H. The company has demonstrated non-clinical improvement of therapeutic efficacy of other cancer drugs like Mitomycin C and Epirubicin, when combined with Alpa1H and successfully continued with the Phase I/II study of Alpha1H in bladder cancer patients.
There is evidence of good financial management in this project. The amount of financial resources utilized to date is proportionate to the achievements of the project to date”.
Hamlet Pharma will now receive the second payment from the EIC Accelerator Horizon 2020 fund of approximately 6,7 million SEK. The third payment is expected at the end of the program.
This disclosure contains information that Hamlet is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 09-07-2021 09:47 CET.
For more information, please contact
Catharina Svanborg, Chairperson of the board, Hamlet Pharma, +46 709 42 65 49
Mats Persson, CEO Hamlet Pharma, +46 705 17 67 57
About HAMLET Pharma
HAMLET Pharma, listed on Spotlight, develops drugs based on the unique tumoricidal protein-lipid complex, HAMLET, formed by two natural and harmless molecules found in breast milk. Development focuses primarily on drugs, for the treatment and prevention of cancer. HAMLET kills tumour cells and has proven safe in proof-of-concept studies in animal models. Alpha1H is the synthetic variant of HAMLET, which has enabled development of the agent for clinical trials. Alpha1H kills different types of tumour cells and has demonstrated therapeutic effects on bladder cancer in animal models. Hamlet Pharma has one ongoing Phase I/II clinical trial with Alpha1H in patients with bladder cancer, a costly form of cancer that is difficult to treat and intends to expand its activities into other types of cancer. The first results from the ongoing clinical Phase I/II study shows no side effects of Alpha1H, indicating that the treatment is safe and well tolerated. Alpha1H also demonstrated clinical efficacy compared with patients who received placebo. In addition, Hamlet Pharma develops BAMLET, which is a molecular complex formed by bovine α-lactalbumin and oleic acid. Data from animal models suggest that local BAMLET treatment may be effective against colon cancer.
This project is funded from the European Union’s Horizon 2020 research and innovation program under grant agreement No 954360.
Sprint Bioscience licenses the cancer drug program Vps34 to Deciphera Pharmaceuticals
Sprint Bioscience AB (publ) announces today that the company has licensed its cancer drug program Vps34 to the US pharmaceutical company Deciphera Pharmaceuticals. The license agreement covers exclusive global rights to the program. The agreement has a total potential value of up to USD 277 million,...
Sprint Bioscience utlicensierar cancerläkemedelsprogrammet Vps34 till Deciphera Pharmaceuticals
Sprint Bioscience AB (publ) meddelar idag att bolaget licensierat sitt cancerläkemedelsprogram Vps34 till det amerikanska läkemedelsbolaget Deciphera Pharmaceuticals. Licensavtalet avser de exklusiva globala rättigheterna till programmet. Avtalet har ett sammanlagt potentiellt värde på upp till 277...
Ectin Research AB publicerar utfall i bolagets emission inför notering
Den 29 juli 2021 avslutades teckningstiden i Ectin Research AB:s (”Ectin” eller ”Bolaget”) emission av units (aktier och teckningsoptioner) om totalt initialt cirka 55 MSEK inför notering på Spotlight Stock Market (”Spotlight”). Emissionen tecknades till totalt ci...
Bluelinea a levé près de 2 MEUR par l'exercice de BSA J afin d'accompagner son développement.
Bluelinea, opérateur majeur de la filière «Silver Économie» en France, est heureux d'annoncer le succès de son augmentation de capital par l'exercice des bons de souscription d'actions attribués gratuitement à tous les act...